Amendments to The Claims

Please cancel claims 15 and 33 without prejudice. Please amend claim 13. This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-12. (Canceled)

13. (Currently amended) A method for activating a membrane of a cell, comprising contacting the cell with an effective amount of a biglycan therapeutic, wherein the biglycan therapeutic ~~activates~~ potentiates agrin-induced phosphorylation of muscle, skeletal, receptor tyrosine kinase (MuSK) on the cell.

14. (Canceled)

15. (Canceled)

16. (Original) The method of claim 13, wherein the biglycan therapeutic upregulates utrophin levels.

17-31. (Canceled)

32. (Previously presented) The method of claim 13, wherein the biglycan therapeutic is a polypeptide including a biglycan amino acid sequence which is at least about 90% identical to SEQ ID NO: 9.

33. (Canceled)

34. (Previously presented) The method of claim 32, wherein the biglycan amino acid sequence includes one or more Leucine Rich Repeats (LRRs) of human biglycan having SEQ ID NO: 9.

35. (Previously presented) The method of claim 32, wherein the polypeptide is derivatized with one or more glycosaminoglycan (GAG) side chains.

36. (Previously presented) The method of claim 32, wherein the biglycan amino acid sequence is at least about 90% identical to amino acids 38-365 of SEQ ID NO: 9.

37. (Previously presented) The method of claim 32, wherein the biglycan amino acid sequence is at least about 95% identical to amino acids 38-365 of SEQ ID NO: 9.

38. (Previously presented) The method of claim 32, wherein the cell is a muscle cell.

39. (Currently amended) The method of claim 13, further comprising assaying activity of muscle, skeletal, receptor tyrosine kinase (MuSK), wherein elevated activity of MuSK indicates activation of the ~~postsynaptic~~ membrane of the cell.